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SUMMARY
CHF is a progressive disease which has a high morbidity and mortality despite treat-
ment with ACEI, diuretics and digoxin. With the aging of the population and the
progress in the treatment of ischemic heart diseases and hypertension the number
of patients with CHF is increasing, making CHF a large socio-economic and epide-
miological problem. In the pathophysiology of CHF vasoconstriction is thought to
play a key role. Adjunctive vasodilation, on top of the above mentioned treatment,
may be potentially useful. Calcium channel blockers are arterial vasodilators and are
used in the setting of ischemic heart disease and hypertension. Since hypertension
and ischemic heart disease are the underlying etiology in 60-700/o of the patients
with CHE expectations were high regarding the potential of calcium channel blockers
for CHE However, in clinical practice the Íïrst generation calcium channel blockers,
diltiazem, verapamil and nifidipine gave overall results which were thought to be due
to their negative inotropism and neurohumoral activation. Second generation cal-
cium channel blockers (mainly belonging to the dihydropyridines class) were ex-
pected to be of more value in patients with CHF as they were vascular selective,
thus not inducing negative inotropism at dosages already giving clinically relevant
vasodilation. Furthermore they have a slow onset of action to prevent reflex sympa-
thetic stimulation. In this thesis we sought whether these newer dihydropyridines
could be of value in patients with CHE In the appendices clinical, experimental stud-
ies, and a review article are reported. The clinical studies in patients with CHF evalu-
ated the effects of long term dihydropyridines treatment on cardiopulmonary exer-
cise parameters and on plasma neurohormones (appendix 1,2 and 4), on acute and
long-term hemodynamics (appendix 2-4) and on diastolic function (appendix 3). Ef-
fects were tested both on top of ACEI (appendix 2,4) or versus ACEI (appendix 1,4).
The predictive and prognostic value of submaximal exercise testing is reported in
appendix 5. Experimental studies in rats with an experimental myocardial infarction
are presented in appendices 6 and 7. In these studies the effect on endothelial func-
tion, heart rate variabil ity and plasma neurohormones (appendix 6) and on B-
adrenoceptor density (appendix 7) were studied.
ln appendix | , the results oí a double blind, randomized study comparing the dihydro-
pyridine felodipine, and the angiotensin converting enzyme inhibitor enalapril are
presented. All 46 patients had symptoms of CHF despite treatment with diuretics
and digoxin. Patients had a peak oxygen consumption below 20 ml.min-'.kg-' and a
left ventricular ejection fraction less than 0.40. After l6 weeks of therapy there were
no statistically significant differences in peak oxygen consumption (felodipine * 1.6,
enalapril *2.5 ml.min r.lg r) and exercise tolerance (felodipine *6 | seconds, enalapril
*64 seconds). Quality-of-life parameters were affected slightly better by felodipine
than by enalapril (p<0.05). Plasma norepinephrine decreased by 143 pg.mlr with
enalapril and by l2 pg.ml I with felodipine (p=NS between groups). With regards to
safety no influence was seen on ambulatory electrocardiographic monitoring or labo-
ratory data. Felodipine treated patients had significantly more vasodilatory induced
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side effects. These data suggest that | 6 week treatment of felodipine or enalapril has
comparable effects on exercise parameters in patients with CHF Overall neurohu-
moral activation was not observed with either drug.
In appendix 2 a placebo-controlled, double-blind, parallel group study of I weeks
evaluating the efficacy and safety of the dihydropyridine calcium channel blocker
lacidipine in 25 patients with CHF is presented. Results from cardiopulmonary exer-
cise tests, invasive hemodynamics, echocardiography and neurohormones at rest,
assessed at baseline and after I weeks therapy, were analyzed. All patients were
symptomatic despite treatment with ACEI, digoxin and diuretics. Treatment with
lacidipine 4 mg once daily as compared to placebo treatment significantly improved
peak oxygen consumption (p<0.02), cardiac index (p<0.01) and stroke volume
(p<0.03) paralled by a decrease in systemic vascular resistance (p < 0.03) and arte-
riovenous orygen content difference (p< 0.01). Lacidipine did not influence plasma
norepinephrine, plasma renin activity or aldosteron. The global assessment of effi-
cacy by both investigator and patient suggested a trend for improvement on lacidipine
treatment. Lacidipine was generally well tolerated, although worsening of CHF oc-
curred in I patient. The results from this study with lacidipine in patients with CHF
demonstrate that a dihydropyridine may be of additive value as an adjunct to opti-
mal, including ACEI, therapy in CHF patients.
In appendix 3, an acute hemodynamic study is reported comparing the archetype
dihydropyridine, niíedipine, with a second generation dihydropyridine isradipine. In
20 patients with left ventricular ejection fraction below 0.40 measurements with a
nuclear stethoscope were taken at rest and during right atrial pacing. The drugs
were given in equihypotensive dose. Both systolic and diastolic parameters improved
equally with isradipine and nifedipine. Left ventricular ejection fraction and cardiac
output increased due to peripheral vasodilatation. A negative inotropic effect was
noted in patients at rest with both medications, but not during pacing-induced ischemia.
With either medication, the time constant of relaxation and the end-diastolic elastic-
ity constant decreased during pacing, indicating improvement in diastolic function.
In appendix 4 a review is given of clinical studies, reported since 1990, in patients
with CHF and treated with a second generation dihydropyridine calcium channel
blocker. This review sought to evaluate the value of these drugs in patients with
CHE In over 2000 patients with CHE no consistent beneficial effect of second gen-
eration dihydropyridine treatment was observed with regard to exercise tolerance
or functional capacity. Plasma neurohormones were not significantly affected although
it appears that a consistent increase in plasma renin activity can be observed. In
general the data do not support the use of these drugs as standard treatment of CHE
On the other hand, in general no worsening of CHF was seen with these second
generation DHP and it may be suggested that these drugs can be safely given to
patients with CHE who need additional treatment for angina pectoris or hyper-
tension.
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From our clinical studies, and reports in literature, several questions arose regarding
the mechanism by which second generation dihydropyridines may be of value and
another question regarded the use of cardiopulmonary exercise testing in patients
with CHE First of all we were disappointed in the lack of sensitivity of peak oxygen
consumption or highest comparable oxygen consumption to detect differences be-
tween treatment strategies. To test whether other cardiopulmonary exercise pa-
rameters could be of predictive and prognostic value in patients with CHF we con-
ducted a study (appendix 5). In this study of 96 patients with CHF and an eiection
fraction < 0.45 (mean 0.27) we analysed the relationship bewveen initial exercise
parameters and peak oxygen consumption and prognosis. These initial exercise lev-
els appears better to present a patients everyday activity. Significant differences in
several initial stagês parameters were seen. The parameters oxygen pulse and venti-
lation equivalent for oxygen remained as independent predictors of peak oxygen
uptake. In a multivariate Cox proportional hazards model this predicted (from the
intial stages) peak oxygen uptake remained as an independent predictor of mortality.
Thus the initial 6 min parameters of a cardiopulmonary exercise test may have inde-
pendent value in the assessment of clinical severity and prognosis in patients with CHE
Another question that remained after the clinical studies was whether improvement
in endothelial function or upregulation in B-adrenoceptor density could attribute to
the effects of amlodipine in patients with CHE This was studied in rats after a myo-
cardial infarction had been induced. In these experiments treatment was started l0
days after infarction and lasted 8 weeks. The rats were sacriÍiced and the post mortem
studies were performed. With regard to endothelium dependent vasorela<ation of
the aorta amlodipine did not have a beneficial effect as compared to the control
group (appendix 6) and no differences in plasma neurohormones were found.
Amlodipine tended to increase coronary flow as tested in the Langendodf model. In
the other experiment, evaluating a potential effect by amlodipine on B-adrenoceptor
density or heart rate variability, no differences could be demonstrated on these pa-
rameters (appendix f. So our animal experiments could not confirm our hypothesis.
The following conclusion can be drawn from this thesis:
I Available data on second generation dihydropyridines in patients with CHF do not
support the use of these drugs primarily for the treatment of CHF.
2 Second generation dihydropyridines do not increase mortality or morbidity in
patients with compromised left ventricular function.
3 Regarding neurohumoral activation, second generation dihydropyridines do not
induce significant neurohumoral activation nor do they suppress neurohumoral
activation. In addition, other parameters such as heart rate variability and B-
adrenoceptor density were unaffectected in our preclinical experiments, but
matching clinical data are not (yet) available on this issue.
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